STOCK TITAN

Adaptive Biotechnologies Corporation - ADPT STOCK NEWS

Welcome to our dedicated news page for Adaptive Biotechnologies Corporation (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adaptive Biotechnologies Corporation 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adaptive Biotechnologies Corporation 's position in the market.

Rhea-AI Summary
Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential regulatory approval of investigational therapies in lymphoid malignancies by integrating MRD status into clinical studies to evaluate and advance novel therapeutics more quickly and efficiently.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
Rhea-AI Summary
Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of the adaptive immune system into clinical products. The conference call will be webcasted and available for replay on the company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
conferences earnings
-
Rhea-AI Summary
Adaptive Biotechnologies integrates clonoSEQ test into Epic's diagnostics suite, providing easier access to MRD monitoring in blood cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
Rhea-AI Summary
Adaptive Biotechnologies to participate in Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
conferences
Adaptive Biotechnologies Corporation

Nasdaq:ADPT

ADPT Rankings

ADPT Stock Data

411.16M
96.82M
2.83%
97.6%
6.27%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SEATTLE

About ADPT

we are a commercial-stage, biotechnology organization located in the hot biotech locations of seattle, washington and south san francisco, ca. our world class scientists have invented a patent-pending technology that combines advances in high-throughput sequencing with state-of-the-art computer infrastructure to provide an in-depth analysis of the t- and b-cell repertoire, a specific and important part of the immune system. this information is driving the r&d community to support the fights against cancer, auto-immune disease, and much, much more. we're often asked to describe our company culture. it is very easy ... we're a hard working group of top-notch individuals who are passionate about wanting to make a difference in the world. we know our employees are our most valuable asset, and every employee’s contribution is appreciated. open communication and collaboration are always encouraged in every interaction throughout the organization. we have high expectations of ourselves, and